Personalis (NASDAQ:PSNL – Get Free Report) and Icon (NASDAQ:ICLR – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
Earnings & Valuation
This table compares Personalis and Icon”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Personalis | $69.67 million | 21.28 | -$81.27 million | ($1.09) | -12.99 |
| Icon | $8.29 billion | 1.52 | $229.34 million | $4.26 | 38.62 |
Institutional and Insider Ownership
61.9% of Personalis shares are held by institutional investors. Comparatively, 95.6% of Icon shares are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 44.0% of Icon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Personalis and Icon, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Personalis | 2 | 3 | 4 | 0 | 2.22 |
| Icon | 2 | 7 | 7 | 1 | 2.41 |
Personalis currently has a consensus target price of $14.25, suggesting a potential upside of 0.64%. Icon has a consensus target price of $170.40, suggesting a potential upside of 3.58%. Given Icon’s stronger consensus rating and higher possible upside, analysts clearly believe Icon is more favorable than Personalis.
Risk and Volatility
Personalis has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Comparatively, Icon has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
Profitability
This table compares Personalis and Icon’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Personalis | -153.84% | -46.47% | -35.30% |
| Icon | 3.99% | 8.02% | 4.56% |
Summary
Icon beats Personalis on 13 of the 15 factors compared between the two stocks.
About Personalis
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
About Icon
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.
